These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 11568932)

  • 1. Direct current decreases cell viability but not P-glycoprotein expression and function in human multidrug resistant leukemic cells.
    Holandino C; Veiga VF; Rodrigues ML; Morales MM; Capella MA; Alviano CS
    Bioelectromagnetics; 2001 Oct; 22(7):470-8. PubMed ID: 11568932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
    Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
    Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of P-glycoprotein-mediated multidrug resistance in K562 leukemic cells by indole-3-carbinol.
    Arora A; Seth K; Kalra N; Shukla Y
    Toxicol Appl Pharmacol; 2005 Feb; 202(3):237-43. PubMed ID: 15667829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib resistance in multidrug-resistant K562 human leukemic cells.
    Assef Y; Rubio F; Coló G; del Mónaco S; Costas MA; Kotsias BA
    Leuk Res; 2009 May; 33(5):710-6. PubMed ID: 18977528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytometric study of intracellular P-gp expression and reversal of drug resistance.
    Labroille G; Belloc F; Bilhou-Nabera C; Bonnefille S; Bascans E; Boisseau MR; Bernard P; Lacombe F
    Cytometry; 1998 Jun; 32(2):86-94. PubMed ID: 9627221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the human multidrug resistance gene mdr1 in leukemic cells and its application in studying P-glycoprotein antagonists.
    Fu J; Chen Z; Cen J; Ruan C
    Chin Med J (Engl); 2000 Mar; 113(3):228-31. PubMed ID: 11775252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STI571 combined with vincristine greatly suppressed the tumor formation of multidrug-resistant K562 cells in a human-nude mice xenograft model.
    Gao L; Chen L; Fei XH; Qiu HY; Zhou H; Wang JM
    Chin Med J (Engl); 2006 Jun; 119(11):911-8. PubMed ID: 16780770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of p-glycoprotein-mediated multidrug resistance by macrocyclic bisbibenzyl derivatives in adriamycin-resistant human myelogenous leukemia (K562/A02) cells.
    Li X; Sun B; Zhu CJ; Yuan HQ; Shi YQ; Gao J; Li SJ; Lou HX
    Toxicol In Vitro; 2009 Feb; 23(1):29-36. PubMed ID: 18938236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lentivirus-mediated RNA interference reversing the drug-resistance in MDR1 single-factor resistant cell line K562/MDR1.
    Ye X; Liu T; Gong Y; Zheng B; Meng W; Leng Y
    Leuk Res; 2009 Aug; 33(8):1114-9. PubMed ID: 19036441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gamma-linolenic acid modulates the response of multidrug-resistant K562 leukemic cells to anticancer drugs.
    Kong X; Ge H; Chen L; Liu Z; Yin Z; Li P; Li M
    Toxicol In Vitro; 2009 Jun; 23(4):634-9. PubMed ID: 19268700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment of P-gp-positive L1210/VCR cells by verapamil and all-trans retinoic acid induces down-regulation of P-glycoprotein expression and transport activity.
    Sulová Z; Macejová D; Seres M; Sedlák J; Brtko J; Breier A
    Toxicol In Vitro; 2008 Feb; 22(1):96-105. PubMed ID: 17920233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitization and apoptosis augmentation of K562/ADM cells by anti-multidrug resistance gene peptide nucleic acid and antisense oligodeoxyribonucleotide.
    Wei HL; Wu YJ; Jing T; Bai DC; Ma LF
    Acta Pharmacol Sin; 2003 Aug; 24(8):805-11. PubMed ID: 12904281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
    Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH
    Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cytotoxic effect and the multidrug resistance reversing action of lignans from Phyllanthus amarus.
    Leite DF; Kassuya CA; Mazzuco TL; Silvestre A; de Melo LV; Rehder VL; Rumjanek VM; Calixto JB
    Planta Med; 2006 Dec; 72(15):1353-8. PubMed ID: 17054045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New silicon compounds as resistance modifiers against multidrug-resistant cancer cells.
    Molnar J; Mucsi I; Nacsa J; Hevér A; Gyémánt N; Ugocsai K; Hegyes P; Kiessig S; Gaal D; Lage H; Varga A
    Anticancer Res; 2004; 24(2B):865-71. PubMed ID: 15161039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of curcumin on multidrug resistance in resistant human gastric carcinoma cell line SGC7901/VCR.
    Tang XQ; Bi H; Feng JQ; Cao JG
    Acta Pharmacol Sin; 2005 Aug; 26(8):1009-16. PubMed ID: 16038636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
    Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
    J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimultidrug-resistant effect and mechanism of a novel CA-4 analogue MZ3 on leukemia cells.
    Xu D; Fang L; Zhu Q; Hu Y; He Q; Yang B
    Pharmazie; 2008 Jul; 63(7):528-33. PubMed ID: 18717489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition by erythroid differentiation factor (activin A) of P-glycoprotein expression in multidrug-resistant human K562 erythroleukemia cells.
    Okabe-Kado J; Hayashi M; Honma Y; Hozumi M; Tsuruo T
    Cancer Res; 1991 May; 51(10):2582-6. PubMed ID: 1673636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential.
    Alemán C; Annereau JP; Liang XJ; Cardarelli CO; Taylor B; Yin JJ; Aszalos A; Gottesman MM
    Cancer Res; 2003 Jun; 63(12):3084-91. PubMed ID: 12810633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.